Jody A. Charnow

Editor

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

Nephrology

Fractures More Common in Children With Glomerular Disease

Jody A. Charnow

October 4, 2022

Girls with glomerular disease have a 1.6-fold greater likelihood of experiencing a fracture of any type compared with girls in the general pediatric population, data show.

Bladder Cancer

Enfortumab Vedotin Plus Pembrolizumab ‘Promising’ for Untreated Advanced Urothelial Carcinoma

Jody A. Charnow

October 3, 2022

Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.

Prostate Cancer

Metastatic Prostate Cancer: Investigators Ponder New Path to Improve Survival

Jody A. Charnow

September 30, 2022

Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.

Prostate Cancer

PSMA PET/CT Lymph Node Staging Can Predict Prostate Cancer Surgery Outcomes

Jody A. Charnow

September 29, 2022

Pelvic lymph node metastases visualized on PSMA PET/CT prior to prostate cancer surgery independently predicts an increased risk for biochemical disease progression, a study found.

Acute Kidney Injury

Post-Contrast Acute Kidney Injury Linked to Transient Hypotension

Jody A. Charnow

September 28, 2022

Transient hypotension increases the risk for post-contrast acute kidney injury following computed tomography with contrast media, according to investigators.

Lupus Nephritis

Kidney Failure Predictor in Lupus Nephritis Identified

Jody A. Charnow

September 26, 2022

Persistent isolated C3 hypocomplementemia is associated with an increased risk for end-stage kidney disease or death in patients with proliferative lupus nephritis, a study revealed.

NKF 2017-obese patient in doctor office, obesity blood pressure

Chronic Kidney Disease (CKD)

Apparent Treatment-Resistant Hypertension Common in CKD

Jody A. Charnow

September 23, 2022

Most patients with CKD and apparent treatment-resistant hypertension had uncontrolled resistant hypertension or refractory hypertension.

Contrary to some news headlines, monitoring prostate cancer has different survival implications than

Kidney Cancer

Real-World Data Support Nivolumab + Ipilimumab for First-Line mRCC Therapy

Jody A. Charnow

September 22, 2022

Study revealed an objective response rate consistent with that observed in the CheckMate 214 clinical trial and a low rate of treatment-related adverse events.

Prostate Cancer

Greater PSA Decline Predicts Better 177Lu-PSMA-617 Outcomes in mCRPC

Jody A. Charnow

September 21, 2022

Latest findings are from a post hoc analysis of the phase 3 VISION trial.

Prostate Cancer

Study: 177Lutetium-PSMA-617 After 223Radium for mCRPC Safe, Effective

Jody A. Charnow

September 20, 2022

Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…

Next post in Prostate Cancer